Modifier Genes for Sudden Cardiac Death

Authors, Journal, Affiliations, Type, DOI

• Authors: Peter J. Schwartz, Lia Crotti, Alfred L. George Jr
• Journal: European Heart Journal (2018), 39:3925–3931
• Affiliations: Istituto Auxologico Italiano IRCCS, Milan; University of Milano-Bicocca; Northwestern University Feinberg School of Medicine, Chicago
• Type: Clinical review / translational medicine
• DOI: https://doi.org/10.1093/eurheartj/ehy502

Overview

Modifier genes are genetic factors that modify in either direction the phenotypic consequences of a disease-causing mutation, thereby explaining incomplete penetrance and variable expressivity of Mendelian arrhythmia disorders. This review examines known and candidate modifier genes for SCD in two contexts: congenital LQTS (where modifier gene evidence is most established) and ventricular fibrillation during acute myocardial infarction (where GWAS evidence is emerging but unreplicated). NOS1AP emerges as the most validated modifier — discovered via GWAS for QT duration, confirmed across multiple LQTS founder populations, and extending to drug-induced LQTS. The iPSC-CM physiological genomics approach illustrates how novel protective and aggravating modifiers can be identified without candidate-gene bias.

Keywords

Genetics, Long QT syndrome, Acute myocardial infarction, Genetic variants, Genetic modifiers

Key Takeaways

Concepts and Principles of Modifier Genes

• Incomplete penetrance and variable expressivity in monogenic arrhythmia disorders (including identical mutations within the same family) are partially explained by modifier genes — genetic factors that increase or decrease disease risk independently of the primary mutation.
• Modifier genes span coding and noncoding regions (intragenic), or intergenic regions. Variants range from ultra-rare (<1/20,000) to common (>1%). As a general rule, rare variants have larger individual effect sizes but lower probability of being identified; common variants have smaller effects but are far more tractable via GWAS.
• Candidate modifier gene categories: (i) genes modifying the arrhythmogenic substrate (ion channel genes, modulators, subunits); (ii) genes governing intracellular calcium cycling; (iii) genes affecting autonomic tone and adrenergic responsiveness (sympathetic/parasympathetic balance, catecholamine magnitude).
• LQTS is particularly suited to modifier gene research: well-defined phenotype (QT interval + hard endpoints), relatively common prevalence (~1/2000), and availability of founder populations carrying identical primary mutations.

Intragenic Modifiers of LQTS

• KCNH2-K897T: Common coding variant on the opposite allele from a primary KCNH2 loss-of-function mutation (p.A1116V) converted a latent, asymptomatic mutation into symptomatic LQTS with cardiac arrest. Co-expression in vitro demonstrated markedly lower IKr. Same variant aggravates LQT1 (KCNQ1 mutations): in Finnish KCNQ1-G589D carriers, K897T was associated with longer QTc during maximal exercise. KCNH2-K897T was later associated with life-threatening arrhythmias following AMI — showing modifier transfer across disease contexts.
• SCN5A-H558R: Common coding variant that may modify LQTS severity when present on the same allele as a primary mutation; mechanistic basis relates to intersubunit interactions in voltage-gated sodium channels.

Ion Channel Subunit and Regulatory Variants

• KCNE1-D85N: Common coding variant in KCNE1 (regulatory subunit of KCNQ1/IKs channel). Predisposes to both congenital and drug-induced LQTS. In Finnish KCNQ1-G589D families, D85N was associated with greater QT prolongation in males but not females — a sex-specific modifier. Also nominally associated with longer QTc and more cardiac events in LQT2. Mechanism: impaired IKs and IKr repolarizing currents. Clinical note: in asymptomatic borderline QT prolongation with KCNE1-D85N alone, LQTS diagnosis is not made, but avoidance of IKr-blocking drugs is strongly recommended.
• KCNQ1 3'-UTR variants: Three common KCNQ1 variants in the 3'-UTR affect mRNA stability; variants in trans with the wild-type allele lower wild-type KCNQ1 expression relative to mutant, leading to longer QTc and more events in LQT1. Effect is specific to heterozygous KCNQ1 mutation carriers and not replicated in general population QT studies. Replication in three LQT1 founder populations failed — findings require further investigation.

Founder Population Studies

• The South African KCNQ1-A341V founder population (~500 members, ~200 carriers; ancestor emigrated Netherlands → South Africa in 1690 AD) shows high penetrance and clinical severity but substantial phenotypic heterogeneity, enabling modifier gene discovery despite a single primary mutation.
• AKAP9 variants: In the South African LQT1 cohort, variants in AKAP9 (encoding yotiao, a protein kinase A anchoring protein regulating IKs via cAMP-dependent pathways) were associated with greater cardiac event risk and longer QTc in KCNQ1-A341V carriers. Specific variants have uncertain functional effect but may be in linkage disequilibrium with functional AKAP9 variation.
• Adrenergic receptor variants — ADRA2C-Del322-325 and ADRB1-R389: Associated with exaggerated adrenergic responses, faster resting heart rates, and a trend toward more cardiac events in the South African LQT1 population. Suggests that greater epinephrine/norepinephrine release predisposes to triggered or re-entrant arrhythmias in LQTS.
• KCNQ1-rs2074238 (intronic, T allele): Identified in a case-control study of 112 LQTS duos (discordant symptomatic/asymptomatic first-degree relative pairs carrying the same KCNQ1 or KCNH2 mutation). Minor T allele associated with lower arrhythmic risk and shorter QTc. Validated in 336 LQT1 subjects from South African and Finnish founder populations — evidence for a protective modifier. Effect in LQT2 cohort: shorter QTc nominally, no association with events.

NOS1AP — Most Validated LQTS Modifier

• Discovery: GWAS identified NOS1AP (nitric oxide synthase adaptor protein) variants as QT interval determinants in the general population. Two common noncoding NOS1AP variants were then shown to be associated with elevated life-threatening arrhythmia risk in the South African LQT1 founder population.
• Validation: Confirmed in heterogeneous LQTS populations and in a Netherlands LQT2 cohort. NOS1AP variants are also associated with drug-induced LQTS risk. The breadth of validation across disease types and populations makes NOS1AP the most robustly demonstrated LQTS modifier gene.
• Conflicting biology (contradiction): Higher-risk NOS1AP variant alleles correlate with higher gene expression in human ventricular myocardium (from pacemaker/ICD lead extraction). However, NOS1AP overexpression in guinea pig and rat ventricular myocytes shortens APD — the opposite of the expected direction given that risk variants prolong QT. In contrast, suppressing NOS1AP in zebrafish shortens APD. No current animal model reliably recapitulates the human data. Human iPSC-CM studies are needed to resolve this discrepancy.

iPSC-CM Physiological Genomics Approach

• Chai et al. studied a large LQT2 family (KCNH2 pathogenic mutation) with notable intrafamilial phenotypic discordance. iPSC-CMs from severely vs. mildly affected mutation carriers recapitulated the genotype–phenotype discordance in vitro.
• Severely affected iPSC-CMs showed larger L-type calcium current (ICa,L) amplitude despite comparable IKr loss-of-function — pharmacological ICa,L blockade (nisoldipine) shortened APD, confirming an aggravating role for enhanced ICa,L.
• Exome sequencing identified two candidate modifiers:
  • KCNK17 (2-pore domain K⁺ channel) GOF variant — absent in all severely affected members; silencing in mildly affected iPSC-CMs prolonged APD → identified as a protective allele
  • REM2 variant — carried by all severely affected members; overexpression of variant potentiated ICa,L in control iPSC-CMs; CRISPR/Cas9 correction reversed the cellular phenotype → identified as an aggravating allele
• This approach demonstrates synergy of WES + iPSC-CM electrophysiology + genome editing for unbiased modifier discovery.

Clinical Application of Modifier Genes

• LQTS patients carrying a primary mutation plus validated NOS1AP risk alleles may warrant more vigilant monitoring or more aggressive therapy.
• A 61-SNP GWAS-derived QT risk score correlated with drug-induced QTc prolongation in a randomised crossover trial of 3 QT-prolonging drugs. Applying this to LQTS mutation carriers in prospective studies could establish its value.
• Challenge: population-derived risk scores require prospective validation before individual-level clinical application.

Modifier Genes for VF in Acute Myocardial Infarction

• Familial aggregation evidence: SCD in one parent increases SCD risk by 2.6× (Paris Prospective Study, n~7,000, 26 years); SCD in both parents increases risk 9.4×. Dutch and Finnish case-control studies showed familial SCD more frequent in first AMI complicated by VF (43% vs. 25%, OR 2.72).
• Candidate gene studies: SCN5A rare variants associated with VF during AMI (small studies). NOS1AP variants associated with higher SCD risk in white adults (confirmed in Rotterdam Study). KCNH2-K897T associated with life-threatening arrhythmias post-AMI.
• GWAS signals: CXADR (coxsackie-adenovirus receptor gene; CXADR-haploinsufficient mice have delayed cardiac conduction and greater ischaemic arrhythmia) and BAZ2B (bromodomain adjacent zinc finger 2B) achieved genome-wide significance in VF/SCD GWAS. However, replication has been limited and inconsistent — findings remain preliminary.

Limitations of the Document

• Candidate gene approaches are biased by prior knowledge; unbiased GWAS requires very large, well-phenotyped cohorts that are difficult to assemble for acute VF events.
• Founder population findings may not generalise to heterogeneous populations with multiple different primary mutations.
• Most LQTS modifier evidence is retrospective; prospective validation studies are largely lacking.
• NOS1AP biology is contradictory across animal model systems; human cardiomyocyte data are insufficient.
• KCNQ1 3'-UTR modifier findings failed to replicate in three founder populations.
• AMI-VF GWAS hits (CXADR, BAZ2B) are unreplicated; mechanistic links are speculative.
• Individual variant sample sizes are often small for the modifier-gene studies reviewed.

Key Concepts Mentioned

• concepts/Modifier-Genes — central framework of this paper
• concepts/Polygenic-Risk-Score — 61-SNP QT risk score for drug-induced QT prolongation
• concepts/iPSC-Derived-Cardiomyocytes — physiological genomics approach for modifier discovery
• concepts/Sudden-Cardiac-Death — overarching clinical endpoint

Key Entities Mentioned

• entities/NOS1AP — most validated LQTS modifier; also implicated in AMI-VF
• entities/KCNQ1 — primary LQT1 gene; KCNQ1-A341V South African founder population; rs2074238 protective modifier; 3'-UTR variants; AKAP9 interaction
• entities/KCNH2 — primary LQT2 gene; K897T intragenic modifier of LQT1/LQT2/AMI-VF
• entities/SCN5A — H558R intragenic modifier; rare SCN5A variants in AMI-VF
• entities/Long-QT-Syndrome — primary disease context for modifier gene evidence

Wiki Pages Updated

• wiki/sources/modifier-genes-scd-ehj-2018.md — created (this file)
• wiki/sourceindex.md — new entry added
• wiki/wikiindex.md — new concept entry (Modifier-Genes), new entity entry (NOS1AP) added
• wiki/concepts/Modifier-Genes.md — created
• wiki/entities/NOS1AP.md — created
• wiki/entities/KCNQ1.md — updated with KCNQ1-A341V founder data, AKAP9, ADRA2C/ADRB1, rs2074238, 3'-UTR variants
• wiki/entities/KCNH2.md — updated with K897T intragenic modifier role across LQT1, LQT2, AMI-VF
• wiki/entities/Long-QT-Syndrome.md — updated with modifier gene framework
• wiki/concepts/Polygenic-Risk-Score.md — updated with 61-SNP QT risk score and LQTS modifier context